A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Relapsed or Refractory Lymphoid Malignancies Clinical Trial

Official title:

A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01703572
• Other study ID #: 52M51-001
• Status: Completed
• Phase: Phase 1
• Start date: October 2012
• Est. completion date: January 2016

Study information

• Verified date: September 2020
• Source: Mereo BioPharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies. Study includes a dose escalation phase and expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics, biomarkers, and efficacy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: January 2016
• Est. primary completion date: January 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

1. Lymphoid malignancy that has relapsed or is refractory after two or more treatments that are FDA approved or are commonly used clinically.

2. Subjects must have progressive disease requiring therapy. Subjects who are candidates for observation only are not eligible.

3. Subjects are either not currently considered to be candidates or refuse potentially curative therapies including peripheral stem cell or bone marrow transplant

4. Subjects must have measurable disease as per disease specific criteria

5. Must have received their last chemotherapy, biologic, radiotherapy, or investigational therapy at least 4 weeks prior to enrollment; 12 weeks from their last radioimmunotherapy; 3 months if the last therapy was bone marrow/ peripheral stem cell transplant.

6. Age >18 years

7. ECOG performance status <2

8. Normal Ejection Fraction on ECHO scan

9. Subjects must have normal organ and marrow function as defined below:

Absolute neutrophil count >1000/mL Platelets >75,000/mL For subjects with known marrow infiltration, ANC =500 and platelets =30,000 Total bilirubin <1.5 X institutional upper limit of normal (ULN) (<2X ULN for subjects with Gilbert's syndrome) AST (SGOT) and ALT (SGPT) <3 X institutional ULN (for subjects with hepatic involvement <5 X institutional ULN) PT/INR and aPTT within 1.5 X institutional ULN Creatinine <1.5 X institutional ULN OR Creatinine clearance >60 mL/min/1.73 m2 for subjects with creatinine levels above institutional normal

10. Women of childbearing potential must have had a prior hysterectomy or have a negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least 6 months after discontinuation of study drug. Men must also agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and from study entry through at least 6 months after discontinuation of study drug. Should a woman enrolled in the study or a female partner of a man enrolled in the study become pregnant or suspect she is pregnant while participating in this study or within 6 months after discontinuation of study, she should inform the Investigator immediately.

11. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Subjects who meet any of the following criteria will not be eligible for participation in the study:

1. Currently receiving any therapeutic treatment for lymphoid malignancies including other investigational agents

2. Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors

3. Active CNS involvement, uncontrolled seizure disorder, or active neurologic disease

4. History of a Grade 4 allergic reaction attributed to humanized or human monoclonal antibody therapy

5. Significant intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

6. Pregnant women or nursing women

7. Ongoing malignancies or malignancies in remission <3 years other than the lymphoid malignancies included in this trial. Patients with history of known skin cancers including non-melanotic skin cancers within the past 3 years will not be included in this trial. The following prior malignancies are allowable irrespective of when they occurred: in situ carcinoma of the cervix, in situ ductal breast cancer, and low-grade local bladder cancer.

8. Subjects with known HIV infection

9. Known bleeding disorder or coagulopathy

10. Subjects receiving heparin, warfarin, or other similar anticoagulants, except for subjects on low molecular weight heparin for DVT/PE prophylaxis. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents.

11. New York Heart Association Classification II, III, or IV

12. Subjects with a blood pressure of >140/90 mmHg that is not responsive to medical therapy. Subjects taking antihypertensive medications must be taking =2 medications to obtain this level of blood pressure control.

13. Subjects with EKG evidence of ischemia or =Grade 2 ventricular arrhythmia, subjects who have a history of acute myocardial infarction within 6 months, or subjects with unstable angina.

14. Subjects with known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease

15. Subjects with diarrhea at time of enrollment or have an ongoing requirement for anti diarrheal therapy

Related Conditions & MeSH terms

• Neoplasms
• Relapsed or Refractory Lymphoid Malignancies

Intervention

Drug:
• OMP-52M51

Locations

Country	Name	City	State
United States	University of Colorado Hospital, Anschutz Cancer Pavilion	Aurora	Colorado
United States	Duke Cancer Institute	Durham	North Carolina
United States	UF Health Davis Cancer Pavilion and Shands Med Plaza	Gainesville	Florida
United States	UC San Diego Moores Cancer Center	La Jolla	California
United States	Sara Cannon Research Institute	Nashville	Tennessee
United States	Cornell University Division of Hematology and Medical Oncology	New York	New York
United States	NYU Clinical Cancer Center	New York	New York
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	University of Nebraska Medical Center	Omaha	Nebraska
United States	University of Rochester Medical Center	Rochester	New York

Sponsors (1)

Lead Sponsor	Collaborator
OncoMed Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety profile of OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies		Subjects will be assessed for DLTs from Days 0-29. Adverse events will be reported through 30 days after the last dose
Secondary	Pharmacokinetics (PK) of OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies	Apparent half life, AUC, clearance, volume of distribution	PK analyses at various time points following the 1st and 2nd doses, immediately pre and post-dose for all subsequent doses at treatment term, every 4 weeks after discontinuation of study drug or 12 weeks
Secondary	Immunogenicity of OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies		At baseline, every 4 weeks, at treatment termination and every 4 weeks after the discontinuation of the study drug for 12 weeks.
Secondary	Preliminary efficacy of OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies		Evaluation for response will be assessed every 56 days and will be based on disease specific criteria.